Table 3. The five-year overall survival on different clinicopathological factors was used Kaplan Meier and univariate analysis.
| Variable | 5-OS (%) | log-rank test P-value | Univariate analysis | |
|---|---|---|---|---|
| HR | 95%CI | |||
| Sex | 0.345 | |||
| male | 74.1 | 1 | ||
| female | 53.3 | 1.445 | 0.670-3.114 | |
| Age | 0.611 | |||
| ≤64y | 64.0 | 1 | ||
| >64y | 49.5 | 1.218 | 0.569-2.606 | |
| IASLC/ATS/ERS classification risk group (predominant adenocarcinoma) | 0.037 | |||
| high risk | 42.1 | 1 | ||
| middle risk | 61.3 | 0.470 | 0.204-1.082 | |
| low risk | 75.0 | 0.250 | 0.053-1.188 | |
| Differentiation | 0.001 | |||
| poor | 26.0 | 1 | ||
| moderate | 49.0 | 0.951 | 0.393-2.301 | |
| well | 79.4 | 0.238 | 0.092-0.619 | |
| Pleural invasion | 0.744 | |||
| present | 64.7 | 1 | ||
| absent | 60.3 | 0.882 | 0.414-1.879 | |
| Distant metastases | 0.066 | |||
| without | 69.1 | 1 | ||
| with | 50.0 | 5.404 | 0.717-40.723 | |
| Lymph node metastasis | 0.008 | |||
| without | 49.7 | 1 | ||
| with | 49.1 | 2.711 | 1.263-5.822 | |
| T states | 0.101 | |||
| T3/T4 | 33.3 | 1 | ||
| T2 | 58.9 | 0.262 | 0.087-0.791 | |
| T1 | 68.0 | 0.226 | 0.067-0.762 | |
| TNM Stage | <0.001 | |||
| I/II | 65.0 | 1 | ||
| III/IV | 23.7 | 4.538 | 2.076-9.920 | |
| Operation mode | 0.933 | |||
| wedge resection | 73.3 | 1 | ||
| lobectomy/other | 54.7 | 1.047 | 0.362-3.027 | |
| Concentration of CEA (ug/l) | 0.045 | |||
| <5 | 60.6 | 1 | ||
| ≥5 | 61.7 | 2.185 | 0.998-4.780 | |
| YBX1 | 0.044 | |||
| low | 74.9 | 1 | ||
| high | 40.5 | 2.111 | 1.003-4.444 | |
| CDC25a | 0.004 | |||
| low | 79.7 | 1 | ||
| high | 45.5 | 3.124 | 1.370-7.123 | |
Note:
Abbreviations: 5-OS, five-year overall survival; CEA, carcino-embryonic antigen.